Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

amneal pharmaceuticals llc - pemetrexed disodium (unii: 2pku919ba9) (pemetrexed - unii:04q9aiz7no) - pemetrexed for injection is indicated: - in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. - in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous nsclc. - as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. - as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. limitations of use : pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer [see clinical studies (14.1)] . pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothe

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 110.29 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 1102.9 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 551.45 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium -

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pemetrexed disodium hemipentahydrate -

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

dr. reddys laboratories inc - pemetrexed disodium (unii: 2pku919ba9) (pemetrexed - unii:04q9aiz7no) - pemetrexed for injection is indicated for: - in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (nsclc), with no egfr or alk genomic tumor aberrations. - in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, nonsquamous, nsclc. - as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous nsclc whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. - as a single agent for the treatment of patients with recurrent, metastatic non-squamous, nsclc after prior chemotherapy. pemetrexed for injection is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. pemetrexed for injection is contraindicated in patients with a history of

Իսրայել - անգլերեն - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Իսրայել - անգլերեն - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 1000 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Իսրայել - անգլերեն - Ministry of Health

taro international ltd, israel - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg/vial - pemetrexed - 1.pemetrexed taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.pemetrexed taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.pemetrexed taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.pemetrexed taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.